Retifanlimab
Zynyz (retifanlimab) is an antibody pharmaceutical. Retifanlimab was first approved as Zynyz on 2023-03-22. It is used to treat merkel cell carcinoma in the USA. It is known to target programmed cell death protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| neoplasms | D009369 |
Trade Name
FDA
EMA
Zynyz
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| merkel cell carcinoma | EFO_1001471 | D015266 | C4A |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
retifanlimab, Zynyz, Incyte Corporation | |||
| 2030-03-22 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 4 | 2 | 2 | — | — | 7 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 3 | 4 | 1 | — | — | 6 |
| Head and neck neoplasms | D006258 | — | — | 2 | 3 | 1 | — | — | 5 |
| Squamous cell carcinoma | D002294 | — | — | 1 | 1 | 1 | — | — | 3 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 2 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 9 | 4 | — | — | — | 11 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 2 | — | — | — | 4 |
| Melanoma | D008545 | — | — | 3 | 3 | — | — | — | 4 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | 2 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 3 | 1 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | — | — | — | 3 |
| Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | — | 3 | — | — | — | 3 |
| Glioma | D005910 | EFO_0000520 | — | — | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | — | 2 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 2 | — | — | — | 2 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic ductal carcinoma | D021441 | — | — | 2 | — | — | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Retifanlimab |
| INN | retifanlimab |
| Description | Retifanlimab, sold under the brand name Zynyz, is an anti-cancer medication used for the treatment of Merkel cell carcinoma. Retifanlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2079108-44-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298037 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15766 |
| UNII ID | 2Y3T5IF01Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PDCD1
PDCD1
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zynyz – Incyte
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 350 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use